Report overview
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Biomarker Testing. This report contains market size and forecasts of Acute Myeloid Leukemia (AML) Biomarker Testing in global, including the following market information:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Acute Myeloid Leukemia (AML) Biomarker Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Genetic Acute Myeloid Leukemia (AML) Biomarker Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Acute Myeloid Leukemia (AML) Biomarker Testing include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA and Skyline DX B.V., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Acute Myeloid Leukemia (AML) Biomarker Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, by Type, 2022 (%)
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Myeloid Leukemia (AML) Biomarker Testing revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Acute Myeloid Leukemia (AML) Biomarker Testing revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Acute Myeloid Leukemia (AML) Biomarker Testing, market overview.
Chapter 2: Global Acute Myeloid Leukemia (AML) Biomarker Testing market size in revenue.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia (AML) Biomarker Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Myeloid Leukemia (AML) Biomarker Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
